PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs

PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which leads to an increase in the uptake of cholesterol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzmich, Nikolay, Andresyuk, Elena, Porozov, Yuri, Tarasov, Vadim, Samsonov, Mikhail, Preferanskaya, Nina, Veselov, Valery, Alyautdin, Renad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778893/
https://www.ncbi.nlm.nih.gov/pubmed/35056760
http://dx.doi.org/10.3390/molecules27020434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778893/
https://www.ncbi.nlm.nih.gov/pubmed/35056760
http://dx.doi.org/10.3390/molecules27020434

Ejemplares similares